In the shadowed caves of ancient India, Siddhartha Gautama sat under a bodhi tree, wrestling with the hydra-headed beast of ...

New research suggests millions taking GLP-1 weight-loss injections could also face a greater risk of developing a chronic cough.

Researchers this week have added another grisly potential side effect to the GLP-1 class of drugs, this time affecting eye health in some pretty unsightly ways.

Children and teens with type 2 diabetes are more likely to receive insulin than newer GLP-1 receptor agonists, according to a new study published in Pediatrics. Current guidelines from the American ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Investing.com -- Eli Lilly plans to invest $3 billion in China over the next decade to build production capacity for its ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces positive topline results from a U.S. Phase II, 24-week study for its subcutaneous (SQ) depot formulations of small molecule GLP-1 receptor ...

With close to one million downloads, Shotsy is the most popular GLP-1 tracking app on the market, and now meets patients at every stage of their GLP-1 journey.

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

Wegovy users have five times the risk of experiencing permanent sight loss linked to weight loss jabs than those taking other GLP-1 medications.

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of 'eye stroke' (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...